Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 9476Neoplasms 6587Prostatic Neoplasms 4399Colorectal Neoplasms 3977Lung Neoplasms 3642Carcinoma, Non-Small-Cell Lung 3583Pancreatic Neoplasms 2478Carcinoma, Hepatocellular 2411Leukemia, Myeloid, Acute 2265Multiple Myeloma 2120Stomach Neoplasms 2108Neoplasm Metastasis 1911Head and Neck Neoplasms 1869Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1729Brain Neoplasms 1699Rectal Neoplasms 1676Melanoma 1654Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1485Esophageal Neoplasms 1311Glioblastoma 1307Lymphoma, Non-Hodgkin 1204Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

aumolertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor × Clear all
NCT04216121 2024-07-01

LAT-FLOSI

Universitaire Ziekenhuizen KU Leuven

Recruiting
39 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

NCT06102928 2023-10-26

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Kunming Medical University

Phase NA Recruiting
30 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡